IR Biosciences Holdings Inc.’s (IRBS.OB) subsidiary is a development-stage biotechnology company devoted to researching, developing and licensing Homspera® and its derivatives. Homspera is an adult stem cell active compound that has been demonstrated the ability to regenerate and strengthen the immune system as well as enhance wound healing. To further its mission, IR BioSciences has forged a number of study partnerships with industry and academic leaders. For more information, please visit www.immuneregen.com.
- 18 years ago
QualityStocks
IR Biosciences Holdings Inc.’s (IRBS.OB)
Related Post
-
QualityStocksNewsBreaks – Why TruGolf Holdings Inc. (NASDAQ: TRUG) Is ‘One to Watch’
TruGolf (NASDAQ: TRUG) is pursuing a strategic expansion into blockchain-based financial infrastructure through its pending…
-
QualityStocksNewsBreaks – Versus Systems Inc. (NASDAQ: VS) Brings Interactive Experiences to Major Sports and Entertainment Audiences
Versus Systems (NASDAQ: VS) uses gamification and audience engagement technology to help brands, sports teams,…
-
QualityStocksNewsBreaks – BOXABL Inc. (NASDAQ: BXBL) Builds Momentum with Potential 1,500-Home Pipeline
BOXABL (NASDAQ: BXBL) has signed a multiyear purchase agreement with LC Vegas Acquisitions, LLC for…